Company Performance - Owens & Minor reported quarterly earnings of $0.23 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and up from $0.19 per share a year ago, representing a 15% earnings surprise [1] - The company posted revenues of $2.63 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 1.43%, but up from $2.61 billion year-over-year [2] - Over the last four quarters, Owens & Minor has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - The stock has underperformed, losing about 40.6% since the beginning of the year, compared to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.32 on revenues of $2.72 billion, and for the current fiscal year, it is $1.64 on revenues of $11.18 billion [7] - The estimate revisions trend for Owens & Minor is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Owens & Minor belongs, is currently in the bottom 32% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Owens & Minor's stock performance [5]

Group 1 - Kodiak Gas Services reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, and showing an increase from $0.39 per share a year ago, representing an earnings surprise of 7.69% [1] - The company achieved revenues of $329.64 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.06%, and up from $215.49 million year-over-year [2] - Kodiak Gas has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Group 2 - The stock has underperformed, losing about 16.2% since the beginning of the year, compared to the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $336.17 million, and for the current fiscal year, it is $2.09 on revenues of $1.35 billion [7] - The Zacks Industry Rank for Oil and Gas - Mechanical and Equipment is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Group 3 - The estimate revisions trend for Kodiak Gas is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The outlook for the industry can significantly impact stock performance, with the top 50% of Zacks-ranked industries outperforming the bottom 50% by more than 2 to 1 [8]

Core Insights - Veracyte reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a significant improvement from a loss of $0.02 per share a year ago, resulting in an earnings surprise of 55% [1] - The company achieved revenues of $114.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.17% and reflecting a year-over-year increase from $96.84 million [2] - Veracyte has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Veracyte's stock will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings surprise [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.31, with projected revenues of $122.71 million, and for the current fiscal year, the consensus EPS is $1.09 on revenues of $490.64 million [7] Industry Context - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Company Performance - Airgain reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $12.01 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.72%, and down from $14.23 million year-over-year [2] - Over the last four quarters, Airgain has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2][3] Stock Movement and Outlook - Airgain shares have declined approximately 43.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.06 for the coming quarter and -$0.05 for the current fiscal year [4][7] - The estimate revisions trend for Airgain is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Communication - Components industry, to which Airgain belongs, is currently ranked in the bottom 17% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Airgain's stock performance [5]

Core Viewpoint - Central Garden (CENT) reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.99 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 10.64%, with a significant prior quarter surprise of 800% when the company reported earnings of $0.21 per share against an expected loss of $0.03 [2] - Revenue for the quarter was $833.54 million, which fell short of the Zacks Consensus Estimate by 4.76% and decreased from $900.09 million year-over-year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has only topped revenue estimates once [3] Stock Performance and Outlook - Central Garden shares have declined approximately 11% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [4] - The company's earnings outlook is mixed, with current consensus EPS estimates of $1.32 for the upcoming quarter and $2.37 for the current fiscal year, alongside expected revenues of $1.01 billion and $3.23 billion respectively [8] Industry Context - The Consumer Products - Discretionary industry, to which Central Garden belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Central Garden's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

Core Viewpoint - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.62 per share a year ago [1][2] Financial Performance - The company achieved revenues of $82.28 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26% and showing an increase from $78.03 million in the same quarter last year [3] - Inogen has surpassed consensus EPS estimates in all four of the last quarters [2][3] Stock Performance - Inogen shares have declined approximately 22.9% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current Zacks Rank for Inogen is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $91.8 million, and for the current fiscal year, it is -$1.41 on revenues of $352.81 million [8] - The trend of estimate revisions for Inogen is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

分组1 - Vishay Intertechnology reported a quarterly loss of $0.03 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.22 per share a year ago [1] - The company posted revenues of $715.24 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.74%, but down from $746.28 million year-over-year [2] - Vishay shares have declined approximately 20.7% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] 分组2 - The earnings outlook for Vishay is mixed, with the current consensus EPS estimate at $0.08 on revenues of $738.4 million for the coming quarter and $0.53 on $3.05 billion in revenues for the current fiscal year [7] - The Zacks Industry Rank for Semiconductor - Discretes is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.39%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.72, delivering a surprise of -4.35%.Over the last four quarters, the compan ...

Group 1 - Super Micro Computer (SMCI) reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.30 per share, but down from $0.67 per share a year ago, representing an earnings surprise of 3.33% [1] - The company posted revenues of $4.6 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.13%, compared to $3.85 billion in the same quarter last year [2] - Super Micro has outperformed the S&P 500, gaining about 5.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.61 on revenues of $6.69 billion, and for the current fiscal year, it is $2.28 on revenues of $23.16 billion [7] - The Computer-Storage Devices industry, to which Super Micro belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, indicating potential challenges ahead [8] - The estimate revisions trend for Super Micro is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting it may underperform the market in the near future [6]

Group 1 - Standard BioTools reported a quarterly loss of $0.04 per share, which is an improvement from a loss of $0.23 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $40.8 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.73%, but down from $45.54 million year-over-year [2] - Standard BioTools shares have declined approximately 34.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Group 2 - The earnings outlook for Standard BioTools is mixed, with current consensus EPS estimates at -$0.05 for the coming quarter and -$0.16 for the current fiscal year, with revenues expected at $38.9 million and $169.2 million respectively [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]